A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
In this Annual Report, the terms, “we,” “us,” “our” or the “Company” refer to Emmaus Life Sciences, Inc., and its subsidiaries. We are a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, primarily for rare and orphan diseases. Our only product, Endari® (prescription grade L-glutamine oral powder) is approved by the U.S. Food and Drug Administration, or FDA, to reduce the acute complications of sickle cell disease (“SCD”) in adult and pediatric patients five years of age and older. In April 2022, Endari® was approved by the Ministry of Health and Prevention in the United Arab Emirates, or U.A.E, in adults and pediatric patients five years of age and older. In November and December of 2022, we received marketing authorizations for Endari® in Qatar and Kuwait, respectively. In May 2023, we received approval for marketing of Endari to treat SCD from the Bahrain National Health Regulatory Authority.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 12M | 17M | 30M | 18M | 21M | 23M |
| Net Income | -7.3M | -6.5M | -3.7M | -11M | - | - |
| EPS | $-0.12 | $-0.10 | $-0.07 | $-0.21 | $-320.00 | $30.00 |
| Free Cash Flow | 0 | -2.3M | -1.5M | -5.1M | -1.3M | -2.5M |
| ROIC | -4.6% | -21.5% | 25.4% | -13.7% | - | - |
| Gross Margin | 92.2% | 62.7% | 66.6% | 51.1% | 23.2% | 90.3% |
| Debt/Equity | 0.00 | -1.17 | -1.40 | -1.85 | -1.36 | -4.92 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -1.2M | -1.9M | 3.5M | -6.6M | -6.1M | -32K |
| Operating Margin | -10.2% | -11.4% | 12.0% | -35.8% | -29.7% | -0.1% |
| ROE | 0.0% | - | - | - | - | - |
| Shares Outstanding | 64M | 65M | 53M | 51M | 51M | 49M |
Emmaus Life Sciences, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 58.8%. At current prices, the estimated annualized return to fair value is -1.5%.
Emmaus Life Sciences, Inc. (EMMA) has a 5-year average return on invested capital (ROIC) of -3.2%. This is below average and may indicate limited pricing power.
Emmaus Life Sciences, Inc. (EMMA) has a market capitalization of $639K. It is classified as a small-cap stock.
Emmaus Life Sciences, Inc. (EMMA) does not currently pay a regular dividend.
Emmaus Life Sciences, Inc. (EMMA) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Emmaus Life Sciences, Inc. (EMMA) reported annual revenue of $17 million in its most recent fiscal year, based on SEC EDGAR filings.
Emmaus Life Sciences, Inc. (EMMA) has a net profit margin of -38.7%. The company is currently unprofitable.
Emmaus Life Sciences, Inc. (EMMA) generated $-2 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Emmaus Life Sciences, Inc. (EMMA) reported earnings per share (EPS) of $-0.10 in its most recent fiscal year.
Emmaus Life Sciences, Inc. (EMMA) has a 5-year average gross margin of 58.8%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for Emmaus Life Sciences, Inc. (EMMA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Emmaus Life Sciences, Inc. (EMMA) has a book value per share of $-0.88, based on its most recent annual SEC filing.